75 related articles for article (PubMed ID: 23584435)
1. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Awan F; Kochuparambil ST; Falconer DE; Cumpston A; Leadmon S; Watkins K; Deremer D; Jillella A; Craig M; Hamadani M
Bone Marrow Transplant; 2013 Oct; 48(10):1279-84. PubMed ID: 23584435
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma].
Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Micallef IN; Stiff PJ; Stadtmauer EA; Bolwell BJ; Nademanee AP; Maziarz RT; Partisano AM; Marulkar S; DiPersio JF
Am J Hematol; 2013 Dec; 88(12):1017-23. PubMed ID: 23907769
[TBL] [Abstract][Full Text] [Related]
4. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M
Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490
[TBL] [Abstract][Full Text] [Related]
6. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T; Sullivan HC; Hendrickson JE
J Clin Apher; 2024 Jun; 39(3):e22127. PubMed ID: 38803152
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis.
Dill V; Blüm P; Lindemann A; Biederstädt A; Högner M; Götze KS; Bassermann F; Hildebrandt M
Transfusion; 2024 May; 64(5):871-880. PubMed ID: 38600674
[TBL] [Abstract][Full Text] [Related]
8. On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost.
Hou LQ; Liu JR; Gu JL; Chen ML; Kuang LF; Huang BH; Zou WY; Li J
Front Oncol; 2023; 13():1306367. PubMed ID: 38298443
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell mobilization.
Hou LQ; Liu JR; Gu JL; Chen ML; Kuang LF; Huang BH; Zou WY; Li J
Ann Hematol; 2024 May; 103(5):1601-1611. PubMed ID: 38267561
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
[TBL] [Abstract][Full Text] [Related]
11. Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.
Teipel R; Rieprecht S; Trautmann-Grill K; Röllig C; Klötzer C; Zimmer K; Rathaj G; Bach E; Brückner M; Heyn S; Wang SY; Jentzsch M; Schwind S; Kretschmann T; Egger-Heidrich K; Remane Y; Franke GN; von Bonin M; Bornhäuser M; Platzbecker U; Hölig K; Merz M; Vučinić V
Transfusion; 2023 Nov; 63(11):2131-2139. PubMed ID: 37850414
[TBL] [Abstract][Full Text] [Related]
12. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Kauer J; Freundt EP; Schmitt A; Weinhold N; Mai EK; Müller-Tidow C; Goldschmidt H; Raab MS; Kriegsmann K; Sauer S
BMC Cancer; 2023 Nov; 23(1):1132. PubMed ID: 37990162
[TBL] [Abstract][Full Text] [Related]
13. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.
Morris C; Chabannon C; Masszi T; Russell N; Nahi H; Kobbe G; Krejci M; Auner HW; Pohlreich D; Hayden P; Basak GW; Lenhoff S; Schaap N; van Biezen A; Knol C; Iacobelli S; Liu Q; Celanovic M; Garderet L; Kröger N
Bone Marrow Transplant; 2020 Feb; 55(2):356-366. PubMed ID: 31534192
[TBL] [Abstract][Full Text] [Related]
14. Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.
Jantunen E; Partanen A; Turunen A; Varmavuo V; Silvennoinen R
Transfus Med Hemother; 2023 Oct; 50(5):438-447. PubMed ID: 37899993
[TBL] [Abstract][Full Text] [Related]
15. Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients.
Sauer S; Hieke L; Brandt J; Müller-Tidow C; Schmitt A; Kauer J; Kriegsmann K
Transfus Med Hemother; 2023 Oct; 50(5):382-395. PubMed ID: 37899996
[TBL] [Abstract][Full Text] [Related]
16. Prospective Comparative Study of Etoposide plus G-CSF versus G-CSF Alone, Followed by Risk-Adapted Plerixafor for Peripheral Blood Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma: CAtholic REsearch Network for Multiple Myeloma Study (CAREMM-2001).
Park SS; Shin SH; Lee JY; Jeon YW; Yhang SA; Min CK
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835477
[TBL] [Abstract][Full Text] [Related]
17. Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.
Baertsch MA; Kriegsmann K; Pavel P; Bruckner T; Hundemer M; Kriegsmann M; Ho AD; Goldschmidt H; Wuchter P
Transfus Med Hemother; 2018 Jan; 45(1):24-31. PubMed ID: 29593457
[TBL] [Abstract][Full Text] [Related]
18. A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.
Dietz L; Marini J; Hashmi H; McGann M
J Oncol Pharm Pract; 2024 Apr; ():10781552241247472. PubMed ID: 38629183
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
Milone G; Martino M; Leotta S; Spadaro A; Zammit V; Cupri A; Avola G; Camuglia MG; Di Marco A; Scalzulli P; Morelli M; Olivieri A; Tripepi G
Leuk Lymphoma; 2018 Jan; 59(1):42-48. PubMed ID: 28573902
[TBL] [Abstract][Full Text] [Related]
20. Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.
Azar N; Ouzegdouh M; Choquet S; Leblond V
J Clin Apher; 2018 Feb; 33(1):5-13. PubMed ID: 28455878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
